Female, n (%) | 20 (71.4%) | 73 (93.6%) | 0.002 |
Age at diagnosis (years) | 48.1±8.8 | 39.5±12.0 | 0.001 |
Disease duration (years) | 10.1±7.6 | 9.8±5.6 | 0.81 |
RF and/or Anti-CCP positivity, n (%) | 22 (78.6%) | 61 (78.2%) | 0.96 |
Extra-articular involvement | 5 (17.9%) | 23 (29.5) | 0.23 |
ESR (mm/h) | 27.5±18.8 | 20.2±15.2 | 0.044 |
CRP (mg/L) | 13.1±18.3 | 11.0±22.7 | 0.65 |
HAQ score | 0.46±0.5 | 0.61±0.63 | 0.27 |
Prediabetes | 7 (25%) | 8 (10.3%) | 0.055 |
Trigylceride (mg/dL) | 151.0±121.8 | 106.5±46.6 | 0.007 |
mSCORE | 2.9±2.7 | 1.2±2.9 | 0.008 |
mASCVD | 8.8±8.2 | 3.9±6.0 | 0.001 |
Current corticosteroid, n (%) | 15 (53.6%) | 40 (51.3%) | 0.83 |
Current methotrexate, n (%) | 8 (28.6%) | 41 (83.7%) | 0.029 |